Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Myeloma • NCI-CCC Tumor Board Question • University of Washington • NCI-CCC Myeloma Tumor Board Question • Multiple Myeloma
If you are using talquetamab as bridging before BCMA CAR-T therapy, when do you assess for response and/or stop the talquetamab?
Do you routinely extend the talquetamab until 1-2 weeks before lymphodepletion, or do you stop earlier if response is achieved?
Answer from: Medical Oncologist at Academic Institution
I’m not fond of the talq approach based on personal experience, but the data looks quite good. Most patients only get about 2-3 full doses before cells are ready. I aim to get step-up dosing completed and then move to 0.8 mg/kg every 2 weeks. That is generally enough to obtain a durable and de...
Sign In or Register to read more
Answer from: Medical Oncologist at Community Practice
The data to support this use of this T-cell engager was drawn from 134 patients treated with talquetamab, bridging with the intent to receive standard-of-care cilta-cel and ide-cel. The majority of patients started talquetamab after apheresis, except for 19 (14%) who received talquetamab prior to T-...